Probiotic strains and mechanistic insights for the treatment of type 2 diabetes

Hampe, Christiane S.; Roth, Christian

doi:10.1007/s12020-017-1433-z

Cited by 35 publications

(55 citation statements)

References 231 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, re- cent studies have shown that inducing symbiosis improves the clinical course of not only UC [34][35][36][37] but also IBS, [38][39][40][41] checkpoint-inhibitor-induced colitis recognized as immune-related adverse events in patients with cancer, 42 hepatic encephalopathy, 43 Parkinson' s disease, 44 and type 2 diabetes. [45][46][47][48] Conventional methods used to induce symbiosis are administration of probiotics and dietary modification including intake of abun-dant dietary fiber; however, fecal microbiota transplantation (FMT) has attracted attention as a method for dramatically altering the intestinal microbiota. FMT reportedly has the potential to induce remission in some patients with UC [49][50][51][52] and may be an effective therapeutic strategy for 5-ASA intolerance.…”

Section: Discussionmentioning

confidence: 99%

5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis

et al. 2020

View full text Add to dashboard Cite

clinical outcomes of UC have been improved by recently developed therapeutic drugs, 2,3 leading to reduced rates of surgical treatment and higher rates of clinical remission compared with previous conventional therapies. 4,5 However, many of these newly developed therapeutic agents still have limited effectiveness, variable responses, potential adverse events caused by immunosuppression, and pharmacoeconomic issues. 6 5-Aminosalicylic acid (ASA) consists of salazosulfapyridine and mesalazine. It is the first-line drug in induction therapy for mild to moderately active UC and in maintenance therapy for

show abstract

Section: Discussionmentioning

confidence: 99%

5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The authors additionally state that the findings on HbA1c, anti-inflammatory and anti-oxidative effects of probiotics in the clinical setting remain inconsistent. Further obstacles in the evaluation of probiotic strains also lie in the great number of strains studied, and differences in the detection methodology [ 111 ]. All authors agree that the findings in their reviews still imply a need for well-designed clinical studies.…”

Section: Therapymentioning

confidence: 99%

The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into “Old” Diseases

Harsch¹,

Konturek²

2018

Medical Sciences

120

100

View full text Add to dashboard Cite

The investigation of the human microbiome is the most rapidly expanding field in biomedicine. Early studies were undertaken to better understand the role of microbiota in carbohydrate digestion and utilization. These processes include polysaccharide degradation, glycan transport, glycolysis, and short-chain fatty acid production. Recent research has demonstrated that the intricate axis between gut microbiota and the host metabolism is much more complex. Gut microbiota—depending on their composition—have disease-promoting effects but can also possess protective properties. This review focuses on disorders of metabolic syndrome, with special regard to obesity as a prequel to type 2 diabetes, type 2 diabetes itself, and type 1 diabetes. In all these conditions, differences in the composition of the gut microbiota in comparison to healthy people have been reported. Mechanisms of the interaction between microbiota and host that have been characterized thus far include an increase in energy harvest, modulation of free fatty acids—especially butyrate—of bile acids, lipopolysaccharides, gamma-aminobutyric acid (GABA), an impact on toll-like receptors, the endocannabinoid system and “metabolic endotoxinemia” as well as “metabolic infection.” This review will also address the influence of already established therapies for metabolic syndrome and diabetes on the microbiota and the present state of attempts to alter the gut microbiota as a therapeutic strategy.

show abstract

“…Cotillard et al showed that populations with low microbial genome abundance (40%) were relatively more likely to present with pronounced dysmetabolism and low-grade inflammation (Cotillard et al, 2013). Improvement of gut microbiota with probiotics such as Lactobacillus genus (LAB) and Bifidobacteria helps prevent and treat obesity and T2D (Hampe and Roth, 2017). Probiotics may help prevent pathogen colonization by physically interfering with attachment, competing for nutrients, producing antimicrobial substances, and inactivating endotoxins (Medellin-Pena and Griffiths, 2009).…”

Section: Discussionmentioning

confidence: 99%

Preventive Role of Salsalate in Diabetes Is Associated With Reducing Intestinal Inflammation Through Improvement of Gut Dysbiosis in ZDF Rats

et al. 2020

View full text Add to dashboard Cite

A safe and effective approach is needed to prevent and reduce the incidence of diabetes worldwide. The hypoglycemic efficacy of salicylic acid (salsalate, SAL), which has antiinflammatory properties, has been empirically demonstrated in studies conducted at the Joslin Diabetes Center and elsewhere. Here, we investigated the potential role of SAL in preventing the onset of diabetes in Zucker diabetic fatty (ZDF) rats and attempted to elucidate its underlying mechanisms. ZDF and Zucker lean (ZL) rats were administered a high-fat diet with or without SAL intervention, and their relative rates of diabetes were compared. Our results showed that all rats in the placebo group developed diabetes, whereas only 10% of the SAL-treated rats presented with impaired glucose tolerance (IGT). None of the latter progressed to diabetes. Relative to the untreated rats, SAL lowered plasma glucagon and insulin while improving insulin sensitivity and b-cell function. SAL may protect against hyperglycemia by increasing the microbial diversity, ameliorating gut dysbiosis, restoring intestinal epithelial cell connections, inhibiting endotoxin influx into the blood, and attenuating inflammation. Together, these findings suggest that SAL may be a candidate prophylactic therapy against diabetes. The protective role of SAL may be attributed to its ability to reduce intestinal inflammation and improve gut dysbiosis.

show abstract

Probiotic strains and mechanistic insights for the treatment of type 2 diabetes

Cited by 35 publications

References 231 publications

5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis

5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis

The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into “Old” Diseases

Preventive Role of Salsalate in Diabetes Is Associated With Reducing Intestinal Inflammation Through Improvement of Gut Dysbiosis in ZDF Rats

Contact Info

Product

Resources

About